• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med . Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection

tetano

Editor, Senior Moderator
J Clin Med


. 2021 Aug 24;10(17):3775.
doi: 10.3390/jcm10173775.
Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection


Akitaka Yamamoto[SUP] 1 [/SUP], Hideo Wada[SUP] 2 [/SUP], Yuhuko Ichikawa[SUP] 3 [/SUP], Hikaru Mizuno[SUP] 3 [/SUP], Masaki Tomida[SUP] 1 [/SUP], Jun Masuda[SUP] 4 [/SUP], Katsutoshi Makino[SUP] 4 [/SUP], Shuji Kodama[SUP] 5 [/SUP], Masamichi Yoshida[SUP] 5 [/SUP], Shunsuke Fukui[SUP] 6 [/SUP], Isao Moritani[SUP] 6 [/SUP], Hidekazu Inoue[SUP] 6 [/SUP], Katsuya Shiraki[SUP] 6 [/SUP], Hideto Shimpo[SUP] 7 [/SUP]



Affiliations

Abstract

Object: Although many Japanese patients infected with coronavirus disease 2019 (COVID-19) only experience mild symptoms, in some cases a patient's condition deteriorates, resulting in a poor outcome. This study examines the behavior of biomarkers in patients with mild to severe COVID-19.
Methods: The disease severity of 152 COVID-19 patients was classified into mild, moderate I, moderate II, and severe, and the behavior of laboratory biomarkers was examined across these four disease stages.
Results: The median age and male/female ratio increased with severity. The mortality rate was 12.5% in both moderate II and severe stages. Underlying diseases, which were not observed in 45% of mild stage patients, increased with severity. An ROC analysis showed that C-reactive protein (CRP), ferritin, procalcitonin (PCT), hemoglobin (Hb) A1c, albumin, and lactate dehydrogenase (LDH) levels were significantly useful for the differential diagnosis of mild/moderate I stage and moderate II/severe stage. In the severe stage, Hb levels, coagulation time, total protein, and albumin were significantly different on the day of worsening from those observed on the day of admission. The frequency of hemostatic biomarker abnormalities was high in the severe disease stage.
Conclusion: The evaluation of severity is valuable, as the mortality rate was high in the moderate II and severe stages. The levels of CRP, ferritin, PCT, albumin, and LDH were useful markers of severity, and hemostatic abnormalities were frequently observed in patients in the severe disease stage.

Keywords: COVID-19; biomarkers; mild; moderate; severe.
 
Back
Top Bottom